Nature reviews. Clinical oncology

Keyphrases

Publications

volume 21, number 6, 2024

Zeyu Zhang, Yang Du, Xiaojing Shi, Kun Wang, Qiaojun Qu, Qian Liang, Xiaopeng Ma, Kunshan He, Chongwei Chi, Jianqiang Tang, Bo Liu, Jiafu Ji, Jun Wang, Jiahong Dong, Zhenhua Hu, Zhenyu Zhang
NIR-II light in clinical oncology: opportunities and challenges. Nature reviews. Clinical oncology 21 (6) (2024)
Despina Kontos
The promise of AI in personalized breast cancer screening: are we there yet? Nature reviews. Clinical oncology 21 (6) (2024)
Diana Romero
From AACR 2024. Nature reviews. Clinical oncology 21 (6) (2024)
Hung-Yang Kuo, Kabir A Khan, Robert S Kerbel
Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials. Nature reviews. Clinical oncology 21 (6) (2024)
Peter Sidaway
Afami-cel provides a novel treatment option for rare sarcoma subtypes. Nature reviews. Clinical oncology 21 (6) (2024)
Peter Sidaway
Pembrolizumab plus chemoradiotherapy effective in locally advanced cervical cancer. Nature reviews. Clinical oncology 21 (6) (2024)
David Killock
ALND can be safely omitted for patients with sentinel-node macrometastases. Nature reviews. Clinical oncology 21 (6) (2024)
Sebastian G Huayamares, David Loughrey, Hyejin Kim, James E Dahlman, Eric J Sorscher
Nucleic acid-based drugs for patients with solid tumours. Nature reviews. Clinical oncology 21 (6) (2024)
Emily Hoffmann, Max Masthoff, Wolfgang G Kunz, Max Seidensticker, Stefanie Bobe, Mirjam Gerwing, Wolfgang E Berdel, Christoph Schliemann, Cornelius Faber, Moritz Wildgruber
Multiparametric MRI for characterization of the tumour microenvironment. Nature reviews. Clinical oncology 21 (6) (2024)
Diana Romero
Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer. Nature reviews. Clinical oncology 21 (6) (2024)
Diana Romero
From AACR 2024. Nature reviews. Clinical oncology 21 (6) (2024)
Saman Maleki Vareki, Diwakar Davar
Identification of dynamic microbiota signatures in patients with melanoma receiving ICIs: opportunities and challenges. Nature reviews. Clinical oncology 21 (6) (2024)
Peter Sidaway
Afami-cel provides a novel treatment option for rare sarcoma subtypes. Nature reviews. Clinical oncology 21 (6) (2024)
Emily Hoffmann, Max Masthoff, Wolfgang G Kunz, Max Seidensticker, Stefanie Bobe, Mirjam Gerwing, Wolfgang E Berdel, Christoph Schliemann, Cornelius Faber, Moritz Wildgruber
Multiparametric MRI for characterization of the tumour microenvironment. Nature reviews. Clinical oncology 21 (6) (2024)
Zeyu Zhang, Yang Du, Xiaojing Shi, Kun Wang, Qiaojun Qu, Qian Liang, Xiaopeng Ma, Kunshan He, Chongwei Chi, Jianqiang Tang, Bo Liu, Jiafu Ji, Jun Wang, Jiahong Dong, Zhenhua Hu, Zhenyu Zhang
NIR-II light in clinical oncology: opportunities and challenges. Nature reviews. Clinical oncology 21 (6) (2024)

volume 21, number 7, 2024

David H Aggen, Jonathan E Rosenberg
Lighting the torch: intratumoural T cell-to-stroma enrichment score as a predictor of immunotherapy response in urothelial carcinoma. Nature reviews. Clinical oncology 21 (7) (2024)
Peter Sidaway
Adjuvant pembrolizumab improves overall survival in patients with RCC. Nature reviews. Clinical oncology 21 (7) (2024)
Jeong Min Lee, Jae Seok Bae
Enhancing diagnostic precision in liver lesion analysis using a deep learning-based system: opportunities and challenges. Nature reviews. Clinical oncology 21 (7) (2024)
Talía Malagón, Eduardo L Franco, Romina Tejada, Salvatore Vaccarella
Epidemiology of HPV-associated cancers past, present and future: towards prevention and elimination. Nature reviews. Clinical oncology 21 (7) (2024)
Elias J Sayour, David Boczkowski, Duane A Mitchell, Smita K Nair
Cancer mRNA vaccines: clinical advances and future opportunities. Nature reviews. Clinical oncology 21 (7) (2024)
Diana Romero
Adjuvant alectinib improves outcomes in ALK-mutant NSCLC. Nature reviews. Clinical oncology 21 (7) (2024)
Peter Sidaway
Laparoscopic hemihepatectomy is safe and effective. Nature reviews. Clinical oncology 21 (7) (2024)
Diana Romero
Adjuvant alectinib improves outcomes in ALK-mutant NSCLC. Nature reviews. Clinical oncology 21 (7) (2024)
David Killock
Adding ibrutinib to frontline therapy improves outcomes in transplant-eligible patients with MCL. Nature reviews. Clinical oncology 21 (7) (2024)
Peter Sidaway
Ponatinib superior to imatinib in Ph + ALL. Nature reviews. Clinical oncology 21 (7) (2024)
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf Christian Bargou
Bispecific and multispecific antibodies in oncology: opportunities and challenges. Nature reviews. Clinical oncology 21 (7) (2024)
Jennifer N Brudno, James N Kochenderfer
Current understanding and management of CAR T cell-associated toxicities. Nature reviews. Clinical oncology 21 (7) (2024)

volume 21, number 8, 2024

Triparna Sen, Nobuyuki Takahashi, Subhamoy Chakraborty, Naoko Takebe, Amin H Nassar, Nagla A Karim, Sonam Puri, Abdul Rafeh Naqash
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. Nature reviews. Clinical oncology 21 (8) (2024)
Diana Romero
Asciminib is safe and effective in patients with newly diagnosed CML. Nature reviews. Clinical oncology 21 (8) (2024)
Paola Neri, Noemie Leblay, Holly Lee, Annamaria Gulla, Nizar J Bahlis, Kenneth C Anderson
Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins. Nature reviews. Clinical oncology 21 (8) (2024)
Ghulam Rehman Mohyuddin, Aaron M Goodman
Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials. Nature reviews. Clinical oncology 21 (8) (2024)
David Killock
Isatuximab-VRd quadruplet shows promise in transplant-ineligible NDMM. Nature reviews. Clinical oncology 21 (8) (2024)
Christopher Nevala-Plagemann, Ignacio Garrido-Laguna
NALIRIFOX for metastatic pancreatic adenocarcinoma: hope or hype? Nature reviews. Clinical oncology 21 (8) (2024)
Vidya Sankar Viswanathan, Vani Parmar, Anant Madabhushi
Towards equitable AI in oncology. Nature reviews. Clinical oncology 21 (8) (2024)
Peter Sidaway
Neoadjuvant ipilimumab-nivolumab superior to adjuvant nivolumab. Nature reviews. Clinical oncology 21 (8) (2024)
Seong Young Kwon, Hien Thi-Thu Ngo, Jinbae Son, Yeongjin Hong, Jung-Joon Min
Exploiting bacteria for cancer immunotherapy. Nature reviews. Clinical oncology 21 (8) (2024)
Vinay Prasad
CAR T cells in multiple myeloma: lessons learned. Nature reviews. Clinical oncology 21 (8) (2024)
Peter Sidaway
Osimertinib efficacious as maintenance therapy in patients with stage III NSCLC. Nature reviews. Clinical oncology 21 (8) (2024)
Diana Romero
RADICALS-HD sheds light on the role of ADT addition to post-operative radiotherapy. Nature reviews. Clinical oncology 21 (8) (2024)

volume 21, number 9, 2024

Peter Sidaway
Addition of sintilimab to standard therapy improves event-free survival. Nature reviews. Clinical oncology 21 (9) (2024)
David Killock
BrECADD raises the bar in classical Hodgkin lymphoma. Nature reviews. Clinical oncology 21 (9) (2024)
Jeesun Yoon, Do Youn Oh
HER2-targeted therapies beyond breast cancer - an update. Nature reviews. Clinical oncology 21 (9) (2024)
Diana Romero
Promising outcomes with liso-cel in patients with R/R follicular lymphoma. Nature reviews. Clinical oncology 21 (9) (2024)
Duaa H Al-Rawi, Emanuele Lettera, Jun Li, Melody DiBona, Samuel F Bakhoum
Targeting chromosomal instability in patients with cancer. Nature reviews. Clinical oncology 21 (9) (2024)
Julia Chen, Ludvig Larsson, Alexander Swarbrick, Joakim Lundeberg
Spatial landscapes of cancers: insights and opportunities. Nature reviews. Clinical oncology 21 (9) (2024)
Elie Rassy, Nicholas Pavlidis
Predicting tumour origin with cytology-based deep learning: hype or hope? Nature reviews. Clinical oncology 21 (9) (2024)
Maria Vittoria Dieci, Valentina Guarneri
Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain. Nature reviews. Clinical oncology 21 (9) (2024)
Elie Rassy, Nicholas Pavlidis
Predicting tumour origin with cytology-based deep learning: hype or hope? Nature reviews. Clinical oncology 21 (9) (2024)
David Killock
NICHE-2 validates the efficacy of neoadjuvant ICIs in dMMR colon cancer. Nature reviews. Clinical oncology 21 (9) (2024)
David Killock
Vimseltinib improves outcomes in tenosynovial giant cell tumour. Nature reviews. Clinical oncology 21 (9) (2024)